1y return+96.4%S&P 500 +20.9%
3y return+114.3%S&P 500 +68.5%
5y return+26.8%S&P 500 +74.5%
10y return+198.1%S&P 500 +256.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2016: $298 against $357 in the S&P 500.2
Perceptive Advisors LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| PRAXPraxis Precision Medicines I | $681.6M | 10.6% | |
| SYRESpyre Therapeutics Inc | $383.5M | 6.0% | +14.2% |
| CELCCelcuity Inc | $334.5M | 5.2% | +2.2% |
| Ascendis Pharma A/sCUSIP K08588103 | $310.4M | 4.8% | New |
| RYTMRhythm Pharmaceuticals Inc | $287.2M | 4.5% | +9.0% |
| Roivant Sciences LtdCUSIP G76279101 | $286.1M | 4.5% | −2.4% |
| RLAYRelay Therapeutics Inc | $263.9M | 4.1% | +44.7% |
| TVTXTravere Therapeutics Inc | $213.2M | 3.3% | −9.4% |
| KARDKardigan Inc | $195.6M | 3.0% | New |
| Nuvalent IncCUSIP 670703107 | $195.2M | 3.0% | |
| EWTXEdgewise Therapeutics Inc | $177.7M | 2.8% | −1.1% |
| Apogee Therapeutics IncCUSIP 03770N101 | $173.6M | 2.7% | −15.1% |
| AMLXAmylyx Pharmaceuticals Inc | $149.7M | 2.3% | |
| Meiragtx Hldgs PLCCUSIP G59665102 | $145.7M | 2.3% | +4.5% |
| ORKAOruka Therapeutics Inc | $128.0M | 2.0% | −3.6% |
| INBXInhibrx Biosciences Inc | $123.0M | 1.9% | −10.0% |
| PTGXProtagonist Therapeutics Inc | $120.4M | 1.9% | −20.2% |
| SLDBSolid Biosciences Inc | $118.9M | 1.9% | |
| ZYMEZymeworks Inc | $109.3M | 1.7% | +19.2% |
| TNGXTango Therapeutics Inc | $105.6M | 1.6% | +317.9% |
| Immatics N.vCUSIP N44445109 | $105.2M | 1.6% | |
| NRIXNurix Therapeutics Inc | $104.8M | 1.6% | +16.4% |
| BCRXBiocryst Pharmaceuticals Inc | $103.1M | 1.6% | +38.7% |
| RVMDRevolution Medicines Inc | $98.8M | 1.5% | +104.0% |
| AVLNAvalyn Pharmaceuticals Inc | $88.1M | 1.4% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| SYRESpyre Therapeutics Inc | September 30, 2023 | +624.7% | $383.5M |
| INBXInhibrx Biosciences Inc | June 30, 2024 | +568.7% | $123.0M |
| Apogee Therapeutics IncCUSIP 03770N101 | September 30, 2023 | +523.1% | $173.6M |
| AMLXAmylyx Pharmaceuticals Inc | September 30, 2024 | +454.3% | $149.7M |
| Nuvalent IncCUSIP 670703107 | September 30, 2021 | +447.7% | $195.2M |
| PTGXProtagonist Therapeutics Inc | March 31, 2023 | +433.0% | $120.4M |
| ORKAOruka Therapeutics Inc | September 30, 2025 | +394.9% | $128.0M |
| RYTMRhythm Pharmaceuticals Inc | September 30, 2023 | +384.3% | $287.2M |
| SIONSionna Therapeutics Inc | March 31, 2025 | +320.6% | $39.8M |
| TVTXTravere Therapeutics Inc | June 30, 2025 | +283.9% | $213.2M |
Sold off last quarter
- Ascendis Pharma A/sCUSIP 04351P101 was $350.3M
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $208.9M
- Engene Holdings IncCUSIP 29286M105 was $39.7M
- Day One Biopharmaceuticals ICUSIP 23954D109 was $37.6M
- DRUGBright Minds Biosciences Inc was $27.5M
- BLTEBelite Bio Inc was $24.2M
- EVMNEvommune Inc was $10.3M
- NMRANeumora Therapeutics Inc. was $10.0M
- NBIXNeurocrine Biosciences Inc was $8.6M
- IRDOpus Genetics Inc was $8.4M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +22.5% | +14.8% |
| March 31, 2026 | +4.3% | −4.6% |
| December 31, 2025 | +23.5% | +2.4% |
| September 30, 2025 | +24.6% | +7.8% |
| June 30, 2025 | +7.3% | +10.5% |
| March 31, 2025 | −10.2% | −4.6% |
| December 31, 2024 | −8.5% | +2.1% |
| September 30, 2024 | +21.0% | +5.4% |
| June 30, 2024 | −15.6% | +4.0% |
| March 31, 2024 | +8.9% | +10.0% |
| December 31, 2023 | +28.0% | +11.2% |
| September 30, 2023 | −13.1% | −3.6% |
| June 30, 2023 | +8.9% | +8.3% |
| March 31, 2023 | −7.3% | +7.0% |
| December 31, 2022 | −0.7% | +7.1% |
| September 30, 2022 | +16.2% | −5.3% |
| June 30, 2022 | −22.2% | −16.5% |
| March 31, 2022 | −20.7% | −4.9% |
| December 31, 2021 | −11.3% | +10.7% |
| September 30, 2021 | −7.1% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Perceptive Advisors LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1224962&type=13F-HR&dateb=&owner=include&count=40CIK 1224962
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1224962/000101297526000777/Filed August 14, 2026 · accession 0001012975-26-000777